These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 34547366)

  • 1. The SARS-CoV-2-neutralizing capacity of kidney transplant recipients 4 weeks after receiving a second dose of the BNT162b2 vaccine.
    Pedersen RM; Bang LL; Tornby DS; Kierkegaard H; Nilsson AC; Johansen IS; Bistrup C; Jensen TG; Justesen US; Andersen TE
    Kidney Int; 2021 Nov; 100(5):1129-1131. PubMed ID: 34547366
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA Vaccine Immunogenicity in Kidney Transplant Recipients.
    Haller MC; Kaiser RA; Langthaler S; Brandstetter C; Apfalter P; Kerschner H; Cejka D
    Transpl Int; 2021; 35():10026. PubMed ID: 35185359
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial.
    Reindl-Schwaighofer R; Heinzel A; Mayrdorfer M; Jabbour R; Hofbauer TM; Merrelaar A; Eder M; Regele F; Doberer K; Spechtl P; Aschauer C; Koblischke M; Paschen C; Eskandary F; Hu K; Öhler B; Bhandal A; Kleibenböck S; Jagoditsch RI; Reiskopf B; Heger F; Bond G; Böhmig GA; Strassl R; Weseslindtner L; Indra A; Aberle JH; Binder M; Oberbauer R
    JAMA Intern Med; 2022 Feb; 182(2):165-171. PubMed ID: 34928302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kidney transplant recipients vaccinated before transplantation maintain superior humoral response to SARS-CoV-2 vaccine.
    Grupper A; Katchman E; Ben-Yehoyada M; Rabinowich L; Schwartz D; Schwartz IF; Shashar M; Halperin T; Turner D; Goykhman Y; Shibolet O; Levy S; Houri I; Baruch R; Katchman H
    Clin Transplant; 2021 Dec; 35(12):e14478. PubMed ID: 34506644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural SARS-CoV-2 infection results in higher neutralization response against variants of concern compared with 2-dose BNT162b2 vaccination in kidney transplant recipients.
    Benning L; Morath C; Bartenschlager M; Reineke M; Töllner M; Nusshag C; Kälble F; Reichel P; Schaier M; Schnitzler P; Zeier M; Süsal C; Bartenschlager R; Speer C
    Kidney Int; 2022 Mar; 101(3):639-642. PubMed ID: 34954213
    [No Abstract]   [Full Text] [Related]  

  • 6. Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients.
    Hamaya T; Hatakeyama S; Yoneyama T; Tobisawa Y; Kodama H; Fujita T; Murakami R; Fujita N; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Saitoh H; Narumi S; Tomita H; Ohyama C
    Sci Rep; 2022 Apr; 12(1):5876. PubMed ID: 35393481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serological response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients depends on prior exposure to SARS-CoV-2.
    Firket L; Descy J; Seidel L; Bonvoisin C; Bouquegneau A; Grosch S; Jouret F; Weekers L
    Am J Transplant; 2021 Nov; 21(11):3806-3807. PubMed ID: 34153162
    [No Abstract]   [Full Text] [Related]  

  • 8. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study.
    Rozen-Zvi B; Yahav D; Agur T; Zingerman B; Ben-Zvi H; Atamna A; Tau N; Mashraki T; Nesher E; Rahamimov R
    Clin Microbiol Infect; 2021 Aug; 27(8):1173.e1-1173.e4. PubMed ID: 33957273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).
    Korth J; Jahn M; Dorsch O; Anastasiou OE; Sorge-Hädicke B; Eisenberger U; Gäckler A; Dittmer U; Witzke O; Wilde B; Dolff S; Kribben A
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33923063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients.
    Mazzola A; Todesco E; Drouin S; Hazan F; Marot S; Thabut D; Varnous S; Soulié C; Barrou B; Marcelin AG; Conti F
    Clin Infect Dis; 2022 Mar; 74(6):1093-1096. PubMed ID: 34166499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BNT162b2 Third Booster Dose Significantly Increases the Humoral Response Assessed by Both RBD IgG and Neutralizing Antibodies in Renal Transplant Recipients.
    Hod T; Ben-David A; Olmer L; Scott N; Ghinea R; Mor E; Levy I; Indenbaum V; Lustig Y; Grossman E; Rahav G
    Transpl Int; 2022; 35():10239. PubMed ID: 35387393
    [No Abstract]   [Full Text] [Related]  

  • 12. Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients.
    Erol Ç; Yanık Yalçın T; Sarı N; Bayraktar N; Ayvazoğlu Soy E; Yavuz Çolak M; Azap Ö; Arslan H; Haberal M
    Exp Clin Transplant; 2021 Dec; 19(12):1334-1340. PubMed ID: 34951350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Waning antibody response and cellular immunity 6 months after third dose SARS-Cov-2 mRNA BNT162b2 vaccine in kidney transplant recipients.
    Bertrand D; Lemée V; Laurent C; Lemoine M; Hanoy M; Le Roy F; Nezam D; Pruteanu D; Lebourg L; Grange S; Plantier JC; Boyer O; Guerrot D; Candon S
    Am J Transplant; 2022 May; 22(5):1498-1500. PubMed ID: 35007383
    [No Abstract]   [Full Text] [Related]  

  • 14. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus: Not alarming, but should be taken gravely.
    Grupper A; Katchman H
    Am J Transplant; 2021 Aug; 21(8):2909. PubMed ID: 34080285
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients.
    Marinaki S; Adamopoulos S; Degiannis D; Roussos S; Pavlopoulou ID; Hatzakis A; Boletis IN
    Am J Transplant; 2021 Aug; 21(8):2913-2915. PubMed ID: 33864722
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
    Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
    JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients.
    Benotmane I; Bruel T; Planas D; Fafi-Kremer S; Schwartz O; Caillard S
    Kidney Int; 2022 May; 101(5):1073-1076. PubMed ID: 35231463
    [No Abstract]   [Full Text] [Related]  

  • 18. Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients - Implications for the omicron variant: Correspondence.
    Peled Y; Patel JK; Afek A; Mandelboim M
    J Heart Lung Transplant; 2022 Nov; 41(11):1649-1650. PubMed ID: 35961828
    [No Abstract]   [Full Text] [Related]  

  • 19. A third injection of the BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients improves the humoral immune response.
    Masset C; Kerleau C; Garandeau C; Ville S; Cantarovich D; Hourmant M; Kervella D; Houzet A; Guillot-Gueguen C; Guihard I; Giral M; Dantal J; Blancho G
    Kidney Int; 2021 Nov; 100(5):1132-1135. PubMed ID: 34474075
    [No Abstract]   [Full Text] [Related]  

  • 20. A third vaccine dose substantially improves humoral and cellular SARS-CoV-2 immunity in renal transplant recipients with primary humoral nonresponse.
    Westhoff TH; Seibert FS; Anft M; Blazquez-Navarro A; Skrzypczyk S; Zgoura P; Meister TL; Pfaender S; Stumpf J; Hugo C; Viebahn R; Roch T; Stervbo U; Babel N
    Kidney Int; 2021 Nov; 100(5):1135-1136. PubMed ID: 34509489
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.